Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma
We provide in vitro evidence of a novel therapeutic strategy to overcome acquired resistance to PARP inhibitor and platinum in PDAC, using sequential exposure to ceralasertib and olaparib. A sequential regimen should be investigated clinically to circumvent dose limiting toxicity seen in concurrent combinations.
Authors
- David K. Chang (ORCID: https://orcid.org/0000-0002-4821-3078)
- Stephan B. Dreyer (ORCID: https://orcid.org/0000-0001-6134-2096)
- Christian Pilarsky (ORCID: https://orcid.org/0000-0002-7968-3283)
- Rosanna Upstill‐Goddard (ORCID: https://orcid.org/0000-0002-2666-0934)
- Katharine Herbert (ORCID: https://orcid.org/0000-0001-9437-0253)
- Debabrata Mukhopadhyay (ORCID: https://orcid.org/0000-0003-1858-5054)
- Selma Rebus (ORCID: https://orcid.org/0009-0000-0266-1062)
- Fieke E. M. Froeling (ORCID: https://orcid.org/0000-0002-8653-8164)
- Christopher J. Lord (ORCID: https://orcid.org/0000-0002-3226-0515)
- Andrew V. Biankin
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Breast Cancer Now (GB)
- Beatson West of Scotland Cancer Centre (GB)
- Glasgow Royal Infirmary (GB)
- Jacksonville College (US)
- Universitätsklinikum Erlangen (DE)
- Mayo Clinic in Florida (US)
- University of Glasgow (GB)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1038/s41416-025-03051-z
- Citations
- 3
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- AstraZeneca
- Cancer Research UK
- University of Glasgow